Foresite Capital Management V, LLC
Position in LYEL — Lyell Immunopharma, Inc.
CIK 1792206
WEST HOLLYWOOD, CA
Position in LYEL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$6,693,223
-$2,876,961 QoQ
Shares Held
476,386
-0.1% QoQ
Ownership
1.94%
of shares outstanding
% of Portfolio
1.85%
of 13F equity value
Holder Rank
#8
of 87 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Foresite Capital Management V, LLC holds $336,610,422 across 8 Biotechnology names. LYEL ranks #7 (2.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALMS |
Alumis Inc.
|
5,896,995 | $165,941,439 | |
| 2 | CGON |
CG Oncology, Inc.
|
1,079,050 | $76,666,502 | |
| 3 | IRON |
Disc Medicine, Inc.
|
374,069 | $27,359,406 | |
| 4 | PHVS |
Pharvaris N.V.
|
664,142 | $22,966,030 | |
| 5 | EIKN |
Eikon Therapeutics, Inc.
|
1,318,983 | $17,212,728 | |
| 6 | ODTX |
Odyssey Therapeutics, Inc.
|
713,105 | $13,342,194 | |
| 7 | LYEL |
Lyell Immunopharma, Inc.
This page
|
476,386 | $6,693,223 | |
| 8 | NRIX |
Nurix Therapeutics, Inc.
|
265,000 | $6,428,900 |
All Filings in LYEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,693,223 | 476,386 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $9,570,184 | 477,078 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $14,684,460 | 477,078 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $7,747,746 | 477,078 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $3,594,803 | 406,652 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $4,375,579 | 8,133,047 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $5,205,150 | 8,133,047 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||